Novartis Pharma AG: Patients with hidradenitis suppurativa e

In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week 16

Related Keywords

Massachusetts , United States , Trinidad And Tobago , Vinkel , Nordrhein Westfalen , Germany , Switzerland , Trinidad , America , Acta Derm Venereol , Schwierige Zeiten , Clin Aesthet Dermatol , Hidradenitis Suppurativa , Nicole Zinsli Somm , Samir Shah , Parag Mahanti , Richard Jarvis , Novartis Cosentyx , Isabella Zinck , Michael Meo , Dermatol Venereol , Mac Mahon , Satoshi Sugimoto , Julie Masow , Sloan Simpson , Mary Carmichael , Angelika Jahreis , Alexab Kimball , Clinical Development Excellence , Twitter , Beth Israel Deaconess Medical Center , Professor Of Dermatology At Harvard Medical School , Novartis , Exchange Commission , Novartis Europharm , Novartis Pharmaceuticals Corp , Global Head Development Unit Immunology , Harvard Medical , Hidradenitis Suppurativa Clinical Response , Numeric Rating Scale , Rev Dis , Acta Derm , Provides Sustained Improvements , Psoriatic Arthritis , Pooled Safety , Its Effect , Health Related Quality , Patient Reported Outcomes , Patient Relat Outcome , Manuels D , Antoniom L , Skin Disease , Related Quality , Life Rijeka , Dharma , Patients , Hidradenitis , Suppurativa , Xperienced , Sustained , Efficacy , Symptom , Improvement , Ear , When , Reated , Cosentyx ,